L-Nutra – a premier nutri-technology company spearheading longevity science nutrition programs – recently announced the closure of a $47 million first tranche investment in its Series D fundraising. This funding round was led by a personal investment from Stephane Bancel, CEO at Moderna, alongside Brentwood Associates, a Los Angeles-based middle market investment firm.
L-Nutra was founded in 2009 by The University of Southern California (USC) and Dr. Valter Longo (Director of the Longevity Institute at USC). And in partnership with 18 global university research centers, L-Nutra developed the first Nutrition for Longevity pipeline, ProLon aimed at enhancing healthy aging via cellular rejuvenation and improving metabolic health; and Nutrition as Medicine pipeline called L-Nutra Health, aimed at enhancing patients’ chances of remission from diabetes, cancer, autoimmune and cardiovascular diseases.
Headed by Chairman and Chief Executive Officer Joseph Antoun, MD, Ph.D., L-Nutra has become the first nutri-technology company, touting more than 32 clinical trials and 200 worldwide patents.
KEY QUOTES:
“We are proud to have the support of Mr. Stephane Bancel, one of the most successful biotech leaders of our time, who recently enhanced human longevity with Moderna’s COVID vaccine. His personal investment in our company reinforces trust in our cutting-edge science and continued support of our global mission to increase longevity and healthspan across the globe. With Mr. Bancel’s financial support, we can continue to expand ProLon® across global markets. We will also be able to increase access to our first diabetes remission program, allowing patients to significantly reduce their reliance on medication in many cases.”
— Dr. Antoun
“I have been thoroughly impressed by the science led by Dr. Valter Longo, and the products that L-Nutra has brought to market based on his research. I believe that their first nutri-technology product – the 5-day Fasting Mimicking Diet (FMD) – is an important tool to ensure people can live long and healthy lives. I made this personal investment to help L-Nutra continue its development, and to ensure more people have access to its science-based products. I look forward to working with L-Nutra’s management team and Board to maximize the impact that we can have on the quality of lives of many people around the world.”
— Stephane Bancel, CEO at Moderna
